Related references
Note: Only part of the references are listed.3D Imaging and Quantification of the Integrin at a Single-Cell Base on a Multisignal Nanoprobe and Synchrotron Radiation Soft X-ray Tomography Microscopy
Chunyu Zhang et al.
ANALYTICAL CHEMISTRY (2021)
Origin of the Photoluminescence of Metal Nanoclusters: From Metal-Centered Emission to Ligand-Centered Emission
Tai-Qun Yang et al.
NANOMATERIALS (2020)
Quantitative Analysis of Multiple Proteins of Different Invasive Tumor Cell Lines at the Same Single-Cell Level
Xiangchun Zhang et al.
SMALL (2018)
The Precise Diagnosis of Cancer Invasion/Metastasis via 2D Laser Ablation Mass Mapping of Metalloproteinase in Primary Cancer Tissue
Xiangchun Zhang et al.
ACS NANO (2018)
Peptide-Templated Gold Clusters as Enzyme-Like Catalyst Boost Intracellular Oxidative Pressure and Induce Tumor-Specific Cell Apoptosis
Ya Zhang et al.
NANOMATERIALS (2018)
Quantification of HER family receptors in breast cancer
Paolo Nuciforo et al.
BREAST CANCER RESEARCH (2015)
Identification of VAR2CSA Domain-Specific Inhibitory Antibodies of the Plasmodium falciparum Erythrocyte Membrane Protein 1 Using a Novel Flow Cytometry Assay
Harold Obiakor et al.
CLINICAL AND VACCINE IMMUNOLOGY (2013)
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
Michael Untch et al.
LANCET ONCOLOGY (2012)
Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer
Jiannan Wu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
A sandwich enzyme-linked immunosorbent assay for the quantification of insoluble membrane and scaffold proteins
Constanze Geumann et al.
ANALYTICAL BIOCHEMISTRY (2010)
Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
Michael Untch et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Protein-Directed Synthesis of Highly Fluorescent Gold Nanoclusters
Jianping Xie et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2009)
Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy
Masako Kasami et al.
BREAST (2008)
Multistrip Western blotting to increase quantitative data output
Edita Aksamitiene et al.
ELECTROPHORESIS (2007)
Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients - A single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results Database
Gloria J. Morris et al.
CANCER (2007)
The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
Lisa A. Carey et al.
CLINICAL CANCER RESEARCH (2007)
HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support
M Bewick et al.
BONE MARROW TRANSPLANTATION (2001)
Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy
LN Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
